Clinical trial
An Open-Label Evaluation of the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment
NCT04476017 is registered in ClinicalTrials.gov with Supernus Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Evaluation of the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 2020
- Completion date
- March 25, 2022
- Enrollment
- 18 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.